Managing mixed dyslipidemia in special populations.
Managing mixed dyslipidemia in special populations.
复制标题
DOI：
10.1111/j.1751-7141.2009.00057.x
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Miller M
中科院分区：
文献类型：
--
作者：
Miller M
控制低密度脂蛋白胆固醇是心血管护理的主要焦点之一。然而，肥胖和糖尿病这两种全球流行病正在促进相关心脏代谢危险因素的患病率增加。这些因素包括混合性血脂异常，这在总体人群的几个重要亚群中普遍存在。当女性达到并超过更年期时，心血管风险增加，部分反映了血脂异常。此外，患有多囊卵巢综合征的女性表现出一系列与代谢综合征相似的危险因素。某些民族患2型糖尿病或代谢综合征的风险也在增加。在老年人中，血脂异常显著地增加了总体心血管风险，在世界范围内，儿童和青少年出现2型糖尿病或代谢综合征的频率正在增加。医生应该意识到在心脏代谢风险升高的患者中混合性血脂异常的可能性。然而，虽然联合治疗可以成功纠正相关的血脂异常，但与他汀类药物单药治疗相比，添加第二种药物是否能改善冠状动脉风险仍有待确定。
Controlling low-density lipoprotein cholesterol is one of the major focuses of cardiovascular care. However, the twin global pandemics of obesity and diabetes are promoting an increased prevalence of associated cardiometabolic risk factors. These factors include mixed dyslipidemia, which is prevalent among several important subgroups of the overall population. Cardiovascular risk increases as women reach and extend beyond menopause, partly reflective of dyslipidemia. In addition, women with polycystic ovary syndrome display a cluster of risk factors reminiscent of the metabolic syndrome. Certain ethnic groups are also at increased risk of type 2 diabetes or the metabolic syndrome. Dyslipidemia contributes significantly to overall cardiovascular risk in the elderly, and the frequency of children and adolescents presenting with type 2 diabetes or metabolic syndrome is increasing worldwide. Physicians should be aware of the possibility of mixed dyslipidemia in patients at elevated cardiometabolic risk. However, while combination therapy may successfully correct the associated dyslipidemia, it remains to be established whether the addition of a second agent improves coronary risk beyond statin monotherapy.